{"id":69483,"date":"2021-12-15T00:00:00","date_gmt":"2021-12-15T00:00:00","guid":{"rendered":"https:\/\/medgoo.com\/index.php\/2021\/12\/15\/psma-nomogram-may-predict-outcomes-in-prostate-cancer\/"},"modified":"2021-12-17T17:12:06","modified_gmt":"2021-12-17T17:12:06","slug":"psma-nomogram-may-predict-outcomes-in-prostate-cancer","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2021\/12\/15\/psma-nomogram-may-predict-outcomes-in-prostate-cancer\/","title":{"rendered":"PSMA Nomogram May Predict Outcomes in Prostate Cancer"},"content":{"rendered":"<h3>\n<p>Nomogram estimate for individual&#8217;s risk for nonlocalized disease on prostate-specific membrane antigen PET\/CT linked to long-term outcomes<\/p>\n<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>WEDNESDAY, Dec. 15, 2021 (HealthDay News) &#8212; The probability of nonlocalized upstaging on prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) may be prognostic of long-term outcomes in high-risk prostate cancer, according to a study published online Dec. 13 in <em>JAMA Network Open<\/em>.<\/p>\n<p>Michael Xiang, M.D., Ph.D., from the University of California in Los Angeles, and colleagues examined the prognostic significance of a nomogram that models an individual&#8217;s risk for nonlocalized upstaging on PSMA PET\/CT and compared its performance with existing risk-stratification tools in a cohort study of 5,275 patients diagnosed with high-risk or very high-risk prostate cancer. The biopsy Gleason score, percentage positive systematic biopsy scores, clinical T category, and prostate-specific antigen level were included in a nomogram to calculate PSMA upstage probability.<\/p>\n<p>The researchers found that 36 percent of the patients had biochemical recurrence (BCR), 16 percent developed distant metastasis (DM), and 5 percent died of prostate cancer during a median follow-up of 5.1 years. PSMA upstage probability significantly predicted all clinical end points, with eight-year C-indices of 0.63, 0.69, 0.71, and 0.60 for BCR, DM, prostate cancer-specific mortality (PCSM), and overall survival, respectively.  Compared with other risk-stratification tools, the nomogram performed favorably.<\/p>\n<p>&#8220;The PSMA nomogram was designed to predict the positivity of PSMA PET\/CT at initial diagnosis, without regard to eventual clinical outcomes, but interestingly, this PSMA PET\/CT-based tool provided better risk discrimination than existing tools that were designed specifically to predict clinical outcomes,&#8221; Xiang said in a statement.<\/p>\n<p>Several authors disclosed financial ties to the biopharmaceutical industry.<\/p>\n<p><a href=\"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2787066\" target=\"_blank\" rel=\"noopener\">Abstract\/Full Text<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2021 <a href=\"https:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nomogram estimate for individual&#8217;s risk for nonlocalized disease on prostate-specific membrane antigen PET\/CT linked to long-term outcomes<\/p>\n","protected":false},"author":6,"featured_media":69691,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-69483","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/69483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=69483"}],"version-history":[{"count":0,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/69483\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/69691"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=69483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=69483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=69483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}